Fresenius Medical Care Birmingham Home
Fresenius Medical Care - The world’s leading provider of products and services for people with chronic kidney failure - Fresenius Medical Care.
Launch date
Employees
Market cap
CAD28.5b
Enterprise valuation
CAD44.8b (Public information from Sep 2024)
Share price
€34.22 FRE.DE
Birmingham Alabama (HQ)
Financials
Estimates*
| EUR | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 36.3b | 37.5b | 40.8b | 22.3b | 21.7b | 23.0b | 24.1b |
| % growth | 2 % | 3 % | 9 % | (45 %) | (3 %) | 6 % | 5 % |
| EBITDA | 7.2b | 6.9b | 6.5b | 2.7b | 3.6b | 4.0b | 4.3b |
| % EBITDA margin | 20 % | 19 % | 16 % | 12 % | 17 % | 18 % | 18 % |
| Profit | 1.7b | 1.8b | 1.4b | (594m) | 826m | 1.7b | 2.0b |
| % profit margin | 5 % | 5 % | 3 % | (3 %) | 4 % | 8 % | 8 % |
| EV / revenue | 1.3x | 1.2x | 1.0x | 1.3x | 1.4x | 1.3x | 1.2x |
| EV / EBITDA | 6.3x | 6.3x | 6.1x | 10.7x | 8.5x | 7.5x | 6.9x |
| R&D budget | 751m | 805m | 867m | 661m | - | - | - |
| R&D % of revenue | 2 % | 2 % | 2 % | 3 % | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | N/A | IPO | |
| N/A | N/A | Post IPO Equity | |
| N/A | N/A | Seed | |
| N/A | N/A | Seed | |
| N/A | N/A | Seed | |
| N/A | N/A | Seed | |
| N/A | N/A | Post IPO Equity | |
| N/A | N/A | Seed | |
| N/A | N/A | Post IPO Equity | |
| N/A | N/A | Post IPO Equity | |
| Total Funding | - | ||